Institut für Experimentelle Onkologie

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
Klümper, Niklas; Tran, Ngoc Khanh; Zschäbitz, Stefanie; Hahn, Oliver; Büttner, Thomas; Roghmann, Florian; Bolenz, Christian; Zengerling, Friedemann; Schwab, Constantin; Nagy, Dora; Toma, Marieta; Kristiansen, Glen; Heers, Hendrik; Ivanyi, Philipp; Niegisch, Günter; Grunewald, Camilla Marisa; Darr, Christopher; Farid, Arian; Schlack, Katrin; Abbas, Mahmoud; Aydogdu, Can; Casuscelli, Jozefina; Mokry, Theresa; Mayr, Michael; Niedersüß-Beke, Dora; Rausch, Steffen; Dietrich, Dimo; Saal, Jonas; Ellinger, Jörg; Ritter, Manuel; Alajati, Abdullah; Kuppe, Christoph; Meeks, Joshua; Vera Badillo, Francisco E.; Nakauma-González, J. Alberto; Boormans, Joost; Junker, Kerstin; Hartmann, Arndt; Grünwald, Viktor; Hölzel, Michael; Eckstein, Markus (2024-04-24)
<strong>PURPOSE</strong> The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet ...